Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Auctus Growth Plc LSE:AUCT London Ordinary Share GB00BNGMVP25 ORD GBP0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 26.50 - 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 0.0 -0.1 -2.1 - 1

Auctus Growth Share Discussion Threads

Showing 251 to 272 of 275 messages
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
MASSIVE POTENTIAL: HeiQ Plc Concludes acquisition of majority stake in Spanish medical device manufacturer HeiQ Plc (LSE:HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce that it has completed the acquisition of a majority stake in a leading Spanish mask manufacturer, MasFabEs, further to entering into a joint venture outlined in the Company's Prospectus. The manufacturer has been renamed HeiQ Medica S.L. and will manufacture medical devices with HeiQ's cutting-edge textile technologies. MasFabEs has already been producing OTC (over the counter) medical device Type IIR surgical masks (certified for use in a close clinical environments), enhanced with HeiQ Viroblock technology, since the beginning of the pandemic. To date, over 1 billion community face coverings as well as medical masks enhanced with HeiQ Viroblock technology have been sold and the technology is already being used by more than 150 major mask brands such as Burberry. The Company continues to experience strong demand for surgical masks which benefit from the extra protection provided by its Swiss Technology Award-winning HeiQ Viroblock technology. With a maximum production capacity of 15 million masks per month, enough to cover the needs of entire Switzerland with two masks a day, this acquisition will provide HeiQ with more control over the manufacture of its products. It will also provide the Company with an ideal base from which to establish an R&D hub for medical devices in Europe. Bulk order supply will be prioritised for institutions in the medical and healthcare sectors, such as hospitals, clinics, pharmacies and care homes. The masks will also be available on HeiQ's direct to consumer webshop. HeiQ co-founder and CEO Carlo Centonze said: "As a leading, profitable player in the $10 billion antimicrobial market, this manufacturing capability will ensure that we are well positioned to meet the strong on-going demand that we are experiencing for our products. The acquisition is in line with our stated strategy to deliver shareholder value by building on the significant momentum achieved by HeiQ Viroblock while also growing other innovations within our core product portfolio. The pandemic has changed our behaviour for good. Following the SARS epidemic in Asia in 2003, all medical and healthcare workers now use face masks daily in this region and we are confident that this practice will continue worldwide even when the Covid-19 pandemic is under control. "The third pillar of our growth strategy is focused on launching new high margin innovations which serve high growth markets. We are working on a range of exciting technologies, including a new antimicrobial technology with our long standing Australian partner Xefco, as well as our graphene membrane innovation. We look forward to sharing news of a number of exciting advancements ongoing within our R&D pipeline in the coming months." Pedro Herranz, Co-founder and General Manager of MasFabEs, said: "As a company that was founded expressly to provide "made in Spain" products, hence the name MasFabEs (Mascarillas de Fabricación Española), we were already producing HeiQ Viroblock powered masks and enjoyed an excellent relationship with HeiQ. Their majority participation, distribution reach and their plans for applying their materials innovations to medical devices were received with open arms and we are excited about future developments."
From Shares Magazine.... When a company makes a claim that its fabric coating kills all known bacteria and viruses including Covid-19 within 30 minutes and has a shelf-life of up to seven years, it tends to get attention. The Viroblock product from Swiss-based HeiQ Materials was originally developed as an antimicrobial for the Ebola crisis in 2013 and now it is seeing strong demand following the Covid-19 pandemic. Investors will soon get a chance to buy its shares as HeiQ is coming to the UK stock market on 7 December via a reverse takeover of cash shell Auctus Growth (AUCT:AIM). Oliver Brown, fund manager of MFM UK Primary Opportunities (B905T77), told Shares that the founders happened upon the antimicrobial opportunity after completing long walks in the Swiss mountains and getting complaints from their wives about the smelly clothes. In addition to Viroblock, HeiQ has built a presence in textile performance materials that provide enhanced features such as cooling/heating and water repellence. It boasts blue chip clients such as Swedish company IKEA, luxury goods brand Burberry (BRBY) as well as performance brands North Face, Champion and New Balance. RC Brown, Premier Miton and Amati Global Investors are among the institutional investors backing the company at the stock market listing. Amati fund manager David Stevenson says a key attraction is HeiQ’s intellectual property amassed since 2005 including multiple patents and awards for its innovative technologies. Based on the £140 million valuation at listing, HeiQ will trade at around 3.5 times sales compared to the 7.1 times of infection prevention specialist Tristel (TSTL:AIM), and 4.4 times for antimicrobial products company Byotrol (BYOT:AIM). The company is forecast to see annual sales grow by 50% in 2021 slowing to 30% in later years. Profit for the first half of 2020 was $8.6 million.
Monday it is then.
Ta argy - interesting. Have copied it over to a couple of salient places.
Read and digest: November 20, 2020 HeiQ Viroblock has bagged the coveted Swiss Technology Award 2020! The leading technology prize in Switzerland, Swiss Technology Award, yesterday announced the 2020 prizes, and among all the notable finalist innovations of the year, HeiQ was bestowed the highest honor as First Prize Winner for its breakthrough antiviral textile technology HeiQ Viroblock. This is the most notable recognition for the young company’s innovative spirit and technologies as well as its contribution to stemming the spread of the global pandemic. Developed in record time and launched after the Swiss authorities announced the lockdown in March 2020, HeiQ Viroblock has had a major impact on the global textile industry and is being unprecedently adopted by mills around the world. HeiQ Viroblock is one of the world’s most efficient and effective antiviral/antimicrobial technologies and has been applied by more than 150 brands worldwide to over 1 billion products from face masks, apparels to home textiles, mattresses and curtains to date. The technology that makes HeiQ Viroblock a unique innovation What exemplifies HeiQ Viroblock is its ability to turn any fabric antiviral. It’s among the first textile technologies in the world to be proven effective against SARS-CoV-2 (COVID-19). HeiQ Viroblock consists of a combination of HeiQ’s patent-pending vesicle and silver technologies. The two mechanisms of attack result in an over 99.9% destruction of viruses in 5 minutes that is unrivaled in the industry. HeiQ Viroblock is a unique patent-pending formulation of 72% bio-based ingredients, made with 100% cosmetic-grade materials from the International Nomenclature of Cosmetic Ingredients list. HeiQ Viroblock is also a shining example of Swiss cooperation between academics and the industry. The silver technology was developed at ETHZ (Eidgenössische Technische Hochschule Zürich), the vesicle technology at EPFL (École polytechnique fédérale de Lausanne), and the production was scaled up at FHNW (Fachhochschule Nordwestschweiz). HeiQ Viroblock has demonstrated unparalleled speed from laboratory to consumer With unprecedented speed of a mere two months as compared to average launch time of 12-18 months, HeiQ launched the new antiviral textile technology HeiQ Viroblock on March 16, 2020 – two hours after Switzerland declared a state of emergency. This was made possible with the indispensable support of Swiss research Partner FHNW and the EPFL which helped accelerate product validation. The fast scale-up of production was enabled by the FHNW School of Life Sciences with their new Process Technology Center (PTC) by special permit. With its agile operations and global footprint, HeiQ also brought HeiQ Viroblock face masks and other PPE (personal protection equipment) to different corners of the world where are needed. Now, Swiss consumers can also acquire HeiQ Viroblock enhanced face masks online. Reacting to the news of HeiQ Viroblock winning this year’s Swiss Tech Award, Co-founder and CEO Carlo Centonze says: “I am both amazed and honored that HeiQ has won this award a second time in just ten years, and from among some incredible tech innovation finalists. It confirms our resolve to push the boundaries and push innovations to help the world with its most pressing and imminent problems. This award is recognition for our company and team that have spared no efforts to develop and launch HeiQ Viroblock at such speed and make a valuable contribution to the global pandemic efforts. We remain true to our mission: enhancing the everyday lives of people with smart and efficient textile effects.”
+43% post consolidation. And looks to be an interesting play.
hTTps:// Let's hope it happens - looks very good at first glance.
News on the way? (the "Company" or "Auctus") Potential Reverse Takeover of HeiQ Materials AG and Suspension of Listing. The Company is pleased to announce that it is in advanced discussions with HeiQ Materials AG ("HeiQ") with a view to acquiring its entire issued share capital (the "Acquisition"). The Company also announces that it is simultaneously seeking a placing to raise funding for the enlarged group from institutional investors. HeiQ is a leading, R&D driven, materials innovation company, which provides products and services focused on enhancing the qualities of textiles, primarily within the consumer & medical industries. HeiQ creates innovative technologies that add functionality, comfort, hygiene and sustainability to existing apparel, home textiles, technical textiles, medical textiles and devices and fastmoving consumer goods products. HeiQ's technology is incorporated into over 200 of the world's lifestyle brands in the apparel, medical and home textile markets. Should the Acquisition complete it would constitute a Reverse Take Over ("RTO") under the Listing Rules and the Company would apply for the readmission of its shares to the Official List and the Main Market of the London Stock Exchange. Therefore, at the request of the Company, the FCA has suspended the Company's listing on the standard segment of the Official List and trading on the Main Market of the London Stock Exchange has also been suspended pending either a further announcement on specific details of the RTO, the publication of a prospectus, or an announcement that the RTO is not proceeding. There can be no certainty that the Acquisition will take place and it remains subject to terms being agreed and the approval by the shareholders of the Company. A further announcement will be made in due course.
More of the same. 470k expended out of £1m raised to look for an acquisition. Please take a bow all on the BoD. Well done.
Argy, No one following the TOPS tip bought anything like 30,000 shares: Recent Share Trades for Auctus Growth (AUCT) Date Time Trade Prc Volume Buy/Sell Bid Ask Value 16-Oct-19 08:20:21 27.00 30,000 Sell* 30.00 37.00 8,100 O 14-Oct-19 08:19:40 32.00 1,990 Sell* 32.00 39.00 636.80 O 04-Oct-19 13:32:53 32.00 700 Sell* 32.00 39.00 224.00 O 09-Sep-19 16:10:21 35.00 3,000 Sell* 35.00 42.00 1,050 O 09-Sep-19 14:10:56 42.00 1,000 Buy* 35.00 42.00 420.00 O 09-Sep-19 12:04:41 42.00 1,000 Buy* 35.00 42.00 420.00 O 09-Sep-19 10:58:10 42.00 1,000 Buy* 35.00 42.00 420.00 O 09-Sep-19 10:47:22 39.00 3,000 Buy* 32.00 39.00 1,170 O 06-Sep-19 15:44:16 37.00 798 Buy* 30.00 37.00 295.26 O 06-Sep-19 15:41:28 33.00 3,006 Buy* 26.00 33.00 991.98 O 04-Sep-19 10:33:00 30.00 7,176 Sell* 30.00 37.00 2,153 O 02-Sep-19 08:10:52 33.00 5,000 Sell* 33.00 40.00 1,650 O 29-Aug-19 11:12:22 33.00 1,000 Sell* 33.00 40.00 330.00 O 28-Aug-19 15:06:53 37.00 3,000 Sell* 37.00 44.00 1,110 O 28-Aug-19 14:31:23 44.00 700 Buy* 37.00 44.00 308.00 O 28-Aug-19 09:59:53 42.00 710 Buy* 35.00 42.00 298.20 O 28-Aug-19 09:46:39 40.00 1,069 Buy* 33.00 40.00 427.60 O 27-Aug-19 08:47:40 48.00 -1,456 Buy* 33.00 40.00 -698.88 O 28-Aug-19 08:27:23 35.00 1,456 Sell* 35.00 42.00 509.60 O 27-Aug-19 16:28:35 38.00 5,000 Sell* 38.00 45.00 1,900 O 27-Aug-19 11:54:50 40.00 2,000 Sell* 40.00 47.00 800.00 O 27-Aug-19 09:38:37 43.00 1,129 Buy* 36.00 43.00 485.47 O 27-Aug-19 09:29:05 41.00 6,000 Sell* 41.00 48.00 2,460 O 27-Aug-19 08:47:40 48.00 1,456 Buy* 41.00 48.00 698.88 O 27-Aug-19 08:44:54 48.00 557 Buy* 41.00 48.00 267.36 O 27-Aug-19 08:39:55 42.00 2,000 Buy* 38.00 42.00 840.00 O 27-Aug-19 08:36:30 41.00 1,000 Buy* 37.00 41.00 410.00 O 27-Aug-19 08:31:15 39.00 6,000 Buy* 32.00 36.00 2,340 O 27-Aug-19 08:24:17 35.96 619 Buy* 32.00 36.00 222.59 O 27-Aug-19 08:04:02 35.96 5,000 Buy* 32.00 36.00 1,798 O 27-Aug-19 08:02:32 32.96 5,000 Buy* 29.00 33.00 1,648 O 27-Aug-19 08:02:04 32.96 3,000 Buy* 29.00 33.00 988.80 O 09-Aug-19 15:40:44 30.00 5,000 Buy* 26.00 30.00 1,500 O 09-Aug-19 15:24:08 30.00 10,000 Buy* 26.00 30.00 3,000 O 01-Aug-19 16:22:19 30.00 4,245 Sell* 30.00 34.00 1,274 O Today's 30,000 share seller is a long-term holding throwing in the towel after yet another disappointment from AUCT in the recent interim results, after previously raising hopes of a deal. That is not the faults of TOPS. Also note that the spiel about 'focussing on delivering a near term transaction' is identical to the spiel in the interim results three years previously! - 11/10/2019 10:00 UKREG Auctus Growth Plc Half-year Report " ... Within the Chairman's Statement accompanying the full year accounts ending 31 December 2018, I referred to a potential transaction that was under due diligence at that time. Unfortunately, I am disappointed to report that this transaction could not be concluded principally due to disagreement over the valuation as well as over some other key terms. The harsh reality is that in a competitive marketplace either the quality of opportunities being introduced or the lack finance attached to deals has led to a number of failed processes which has been very frustrating and disappointing for management and shareholders alike. However, the Board continues to actively evaluate a number a potential transactions across a variety of different sectors. At this time no formal agreement has been entered into by the Company however the Board remains focused on delivering a transaction that brings both value and growth potential to the Shareholders of Auctus Growth in the near term. ..." 28/09/2016 14:00 UK Regulatory (RNS & others) Auctus Growth Plc Half-year Report " ... During this financial period the Board has continued to actively evaluate a number a potential transactions across a variety of different sectors. At this time no formal agreement has been entered into by the Company however the Board remains focused on delivering a transaction that brings both value and growth potential to the Shareholders of Auctus Growth in the near term. ..."
hedgehog 100
Mr 30k was presumably a Tops' follower. Sad & stupid.
Stupid trying to trade this stock unless you are the original pump'n dumper (TOPS). Best to just wait for the deal then hopefully reap the rewards if it's a good one. Cue Mr 1456.....sad.
Looks like TOPS bought some (6k) on the 23rd to sell into today's ramp. Same with MILA although looks to have bought those (216,094) on 21st and sold today on the ramp
Thanks, kemche. f
Mischief by tops - nothing else.
A happy 5th. 'shell birthday' to AUCT! And could it finally be about to RTO!! 22/08/2014 07:01 UK Regulatory (RNS & others) Auctus Growth Plc Initial Public Offering "Auctus Growth plc ("Auctus" or the "Company") is pleased to announce the results of its successful placing of 2,440,000 Ordinary Shares (the "Placing") to a list of professional investors and institutions and the initial public offering of its entire share capital, being 2,440,000 Ordinary Shares. Auctus has raised gross proceeds of GBP1,220,000. Auctus has been formed to undertake an acquisition of a target company or business. The Company's efforts in identifying a prospective target company or business will not be limited to a particular sector or geographic region. However, the Company expects to draw on the extensive experience of the Company's founders and its board in sourcing and successfully executing such transactions. The Company is targeting a significant deal; accordingly a listing on the Official List of the FCA, as opposed to a junior market, matches the future ambitions of the Company in terms of scale, quality and appreciation in shareholder value. It is expected that admission to a Standard Listing on the Official List of the FCA will become effective and unconditional dealings in the Ordinary Shares on the London Stock Exchange's main market for listed securities will commence at 8.00 a.m. today under the ticker symbol "AUCT". ..." 29/04/2019 07:00 UK Regulatory (RNS & others) Auctus Growth Plc Final Results " ... I am very conscious of our lack of performance in regards to securing a suitable reverse takeover candidate. Myself and the Board are very appreciative of your patience and remain eager to find a transaction that will ultimately reward all shareholders. In that regard I can confirm that the Board is currently assessing a potential transaction and whilst there can be no guarantee the transaction will proceed the Board is encouraged by the initial due diligence being carried out. ... "
hedgehog 100
First sign of any action for a while. Fingers crossed.
"At this time no formal agreement has been entered into by the Company however the Board remains focused on delivering a transaction that brings both value and growth potential to the Shareholders of Auctus Growth in the near term." Does "near term" now mean "never"?
Down 2p today on no volume. Even the MMs are getting bored! May produce a buying opportunity if they take it down much further.
Jeez, how long does it take?
Another year of great achievement. I continue to hold :( One day Rodders!
Chat Pages: 11  10  9  8  7  6  5  4  3  2  1
ADVFN Advertorial
Your Recent History
Auctus Gro..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220808 16:24:26